Published online before print January 20, 2005, doi: 10.1161/01.STR.0000154856.42135.85
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2005;36:597.)
© 2005 American Heart Association, Inc.
Original Contributions |
Improving Trial Power Through Use of Prognosis-Adjusted End Points
From the Division of Cardiovascular and Medical Sciences (F.B.Y., K.R.L.), Gardiner Institute, Western Infirmary, and the Robertson Centre for Biostatistics (C.J.W.), Boyd Orr Building, University of Glasgow, University Avenue, UK.
Correspondence to Fiona B. Young, Division of Cardiovascular and Medical Sciences, University of Glasgow, Gardiner Institute, Western Infirmary, Glasgow, G11 6NT, UK. E-mail Fby1w{at}clinmed.gla.ac.uk
Background and Purpose— The stroke patient population is heterogeneous, leading to wide variation in outcome caused by differences in age, initial severity, and presence of concomitant disease. Setting an identical recovery target for all patients in intervention trials may conceal individually important therapeutic treatment effects. Instead, a variable end point that takes severity or likely prognosis into account may be more informative.
Methods— We used data from the Glycine Antagonist in Neuroprotection (GAIN) International trial to assess statistical power of various primary end points for intervention trials. We selected prognosis-adjusted cut points based on Barthel Index (BI) or Rankin Scale (RS) using a prognostic model, or assigned a fixed end point within subgroups of patients defined by their Oxford category or National Institutes of Health Stroke Scale (NIHSS) score. We simulated a treatment effect and estimated statistical power with standard formulae.
Results— Assignment of end points using a prognostic model for individual patients increased statistical power, when compared with assigning end points using only the Oxford classification. For the BI, power was increased from 60% to 88% (equivalent to a 49% reduction in sample size if power remains unchanged). With the RS end points, power was increased from 84% to 92% (or a 24% reduction in sample size). Versus a fixed end point for all patients, model-based methods increased power by 22 percentage points for BI
95 and 14 percentage points for RS
1 (effective sample size reductions 43% and 34%).
Conclusion— Prognosis-adjusted end points can increase statistical power compared with fixed end points. Assessment is based on realistic goals for individual patients and yet trial results remain generalizable.
Key Words: clinical trials • stroke, acute
This article has been cited by other articles:
 |
|
 |
|
  H.-C. Diener, K. R. Lees, P. Lyden, J. Grotta, A. Davalos, S. M. Davis, A. Shuaib, T. Ashwood, W. Wasiewski, V. Alderfer, et al. NXY-059 for the Treatment of Acute Stroke: Pooled Analysis of the SAINT I and II Trials Stroke, June 1, 2008; 39(6): 1751 - 1758. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. R. Konig, A. Ziegler, E. Bluhmki, W. Hacke, P. M.W. Bath, R. L. Sacco, H. C. Diener, C. Weimar, and on behalf of the Virtual International Stroke Tria Predicting Long-Term Outcome After Acute Ischemic Stroke: A Simple Index Works in Patients From Controlled Clinical Trials Stroke, June 1, 2008; 39(6): 1821 - 1826. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Saver Novel End Point Analytic Techniques and Interpreting Shifts Across the Entire Range of Outcome Scales in Acute Stroke Trials Stroke, November 1, 2007; 38(11): 3055 - 3062. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bruno, C. Saha, and L. S. Williams Using Change in the National Institutes of Health Stroke Scale to Measure Treatment Effect in Acute Stroke Trials Stroke, March 1, 2006; 37(3): 920 - 921. [Abstract] [Full Text] [PDF]
|
|